Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing ...
RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance Reducing RASH3D19 also reduced tumor ...
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...
CINCINNATI (WKRC) — Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for those living with pancreatic cancer. This trial is ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback